Judith Kelleher-Andersson, Ph.D.
Founder, President and Chief Scientific Officer (CSO)
Dr. Kelleher-Andersson has over fifteen years of experience discovering and developing small-molecule, central nervous system therapeutics in the biotechnology industry. Prior to founding Neuronascent, she directed Drug Development and Research at Neuralstem, Inc., Centaur Pharmaceuticals and Cortex Pharmaceuticals, Inc. While at Neuralstem she discovered a small molecule, therapeutic candidate that is presently in clinical trials. She headed the Alzheimer's disease program in collaboration with Astra-Zeneca while at Centaur, and successfully brought a small-molecule agent to pre-nomination status. Dr. Kelleher-Andersson has over 70 US, European and World patents. She received her BA in chemistry from St. Anselm College, her Ph.D. in biochemistry from the University of Missouri-Columbia and completed post-graduate work at University of California, Los Angeles and University of California, San Francisco.

Kathleen L. Mattis, MBA
Treasurer and Secretary of the Board
Ms. Mattis served as Chief Financial Officer of Neuronascent from November 2006-2010 and Secretary to the Board of Directors since May 2004. From 2004 to 2006, she was the principal business advisor for Neuronascent's fiscal operations. Prior to joining Neuronascent, since 2003, she served as the Chief Financial Officer of J. Craig Venter Institute. Previously, she was Vice President of Finance for Neuralstem, Inc.; Controller at Celera Genomics; Founder, Vice President of Finance and Controller for ARIAD Pharmaceuticals, Inc. and Director of Finance for Centocor, Inc. She also served as Controller of Novo Nordisk Pharmaceuticals, Inc. after holding multiple financial management positions at Squibb Corporation in Princeton, NJ and Kraft, Inc. in Chicago, IL. Ms. Mattis has a BS from Drexel University and MBA from the Wharton School of University of Pennsylvania.